Arm Holdings plc - American Depositary Shares (ARM)

Three Dow giants pair market dominance with the financial strength to keep growing for the next decade.

Brookfield's latest results are a big reason I keep adding to my position.

Jensen Huang has resigned as Nvidia CEO. What does it mean for Nvidia stock?

Nvidia just lost its CEO -- so why is Micron stock down?

Investors may be viewing this company's future as being more dependent on the AI industry than it actually is.

Chip stocks broadly rallied on Wednesday as investors went bargain-hunting. The Philadelphia semiconductor index, or SOX, surged.

A regulatory settlement in Ontario will shrink reported revenue by CAD 105 million while barely denting operating profit, exposing the real earnings power underneath.

Both of these companies are spending heavily today to build the next decade's growth.

AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology

Management is betting on branded hardware over third-party OEM work, a shift that could reshape margins for years to come.

The financial company posted an impressive jump in adjusted earnings.

Definium Therapeutics (NASDAQ:DFTX) plans to submit a new drug application to the U.S. Food and Drug Administration for its LSD formulation DT120 in the first half of next year, following positive results from three Phase 3 studies, Chief Medical Officer Daniel Karlin said. The company intends to s

Management details the phase III trial and U.S. approval timeline for its lead asset.

(BPT) - For Simone Duven, using her hands isn't optional. Paralyzed from the waist down, she relies on them to move her wheelchair, transfer in and out of bed and shift her weight to help prevent pressure sores. When pain began shooting through both wrists, even everyday movements were tough.

The AI data analytics stock is now trading 19% below its October high.

Myomo (NYSEAMERICAN:MYO) reported record third-quarter revenue of $12.3 million, up 22% from a year earlier, and narrowed its full-year revenue guidance as referrals and higher sales of its powered arm braces helped improve operating performance. The company reached approximately break-even adjuste

CAMP4 Therapeutics (NASDAQ:CAMP) expects initial data from its SYNGAP1 clinical program in the first half of 2028, as the company prepares to begin dosing patients with a treatment designed to increase expression of a gene associated with a rare neurological disorder. Chief Executive Officer Josh M

Phase 3 hepatitis C data met its endpoints and funding now extends into mid-2028.

Management outlined AXPAXLI's regulatory path and late-stage trial updates.

Arm shares sank despite an upbeat outlook for the company's new CPU business.

Both of these stocks saw their shares in free fall following earnings.

Only one of the two deals is new business. Is the stock's drop an opening?

The impending change in the political backdrop isn't apt to actually affect the growing demand for its equipment, either.

All three chip stocks are more than half off their peaks. Only one expects its sales growth to keep speeding up.